Financings

Amarantus BioSciences Inc. secured more than $1.1 million in funding through two transactions.

Array BioPharma Inc. closed a $65.7 million public offering selling 18 million shares priced at $3.65 each.

Avexxin AS closed a Series B financing round. Financial details were not disclosed.

Idera Pharmaceuticals Inc. raised $7 million in a private placement by issuing shares and warrants.

Intarcia Therapeutics Inc. completed two financings raising a total of $210 million.

Pearl Therapeutics Inc. closed a Series D financing of $65 million for Phase III studies of PT003 in COPD.

Spherix Inc. sold $2.6 million shares and warrants in a private placement transaction.

Deals

Amarantus BioSciences Inc. and Rainbow BioSciences are planning a joint venture.

AmpliPhi Biosciences Corp. has completed its merger with Special Phage Services.

BiOasis Technologies Inc. entered a research and evaluation agreement with MedImmune Inc.

Colby Pharmaceutical Co. is paying up to $140 million to MannKind Corp. for compounds from its cancer vaccine program.

Crystal Bioscience Inc. and Integral Molecular Inc. have launched a research collaboration to generate panels of chicken MAbs against G protein-coupled receptor and ion channel targets.

Evotec AG and Haplogen GmbH are collaborating on small molecules against viral infectious diseases.

ImmunGene Inc. and Caliber Biotherapeutics LLC launched Valor Biotherapeutics LLC, a joint venture for monoclonal antibody-interferon (mAb-IFN) fusion protein therapeutics targeting cancers.

Pernix Therapeutics Holdings Inc. has acquired Cypress Pharmaceuticals Inc. and Hawthorn Pharmaceuticals Inc.

. . . And More

Clavis Pharma ASA shares fell 87 percent after failure of CO-101 (CP-4126) in a pancreatic cancer trial.

Incyte Corp. earned a $50 million milestone payment from Eli Lilly and Co. based on the start of the rheumatoid arthritis Phase III program for baricitinib.

OvaScience Inc. said its common stock was approved for listing on the OTC Bulletin Board.

Tekmira Pharmaceuticals Inc. has resolved all litigation with Alnylam Pharmaceuticals Inc.